LABORATORY NEWS
-
Predicta Biosciences And CIMA LAB Diagnostics Announce Agreement To Advance Ultrasensitive Blood-Based Diagnostics For Multiple Myeloma And Other Hematological Malignancies
Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, and CIMA LAB Diagnostics from the Clínica Universidad de Navarra, a leading European University Medical Center, today announced a partnership to offer a combined service that integrates CIMA LAB’s flow cytometry capabilities with the GenoPredicta assay.
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio At ASM Microbe 2026
- General Fluidics And Invetech Partner To Accelerate Accessible Diagnostics At The Point Of Care
- Roche Rapidly Develops A PCR Test For Ebola Within Six Days As Rare Bundibugyo Virus Drives Urgent Need For Detection
- Sustainable Sample Management Without Disrupting Operations
ARCHIVED NEWSLETTER
- 05.26.26 -- Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
- 04.21.26 -- Proteomics Tools: A Resurrection
- 04.07.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- 02.24.26 -- Rethinking Disease Modification Through Targeted Immunotherapy
- 02.10.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?